Blockchain Registration Transaction Record

Tonix Expands TONMYA Medicare Coverage to 32M Lives, Sales Force to 150

Tonix Pharmaceuticals secures a second major Medicare agreement for TONMYA, expanding coverage to 32 million lives and increasing its sales force to 150 representatives.

This news matters because it significantly improves access to a novel treatment for fibromyalgia, a chronic pain condition affecting millions of Americans who have had few new options for over 15 years. With TONMYA now covered for 53% of the U.S. population, more patients can afford and receive this therapy, potentially transforming their quality of life. For investors, the expanded payer coverage and enlarged sales force signal strong commercial execution and a growing revenue trajectory for Tonix Pharmaceuticals. The agreement also highlights the company's ability to navigate the complex U.S. healthcare reimbursement landscape, which is critical for the success of any new drug. As Tonix continues to advance its pipeline in CNS and immunology, this milestone reinforces its position as a rising player in the biotech industry.